ITPA polymorphism effects on decrease of hemoglobin during simeprevir, pegylated interferon and ribavirin combination treatment for chronic hepatitis C: ITPA SNP and simeprevir therapy - Kei Morio, Michio Imamura, Yoshiiku Kawakami, Reona Morio, Masahiro Hatooka, Hiromi Kan, Hatsue Fujino, Takayuki Fukuhara, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Ayako Urabe, Satoe Yokoyama, Yuko Nagaoki - Dissemin

Language
Login

Published in

Wiley, Hepatology Research, 12(46), p. 1256-1263, 2016

DOI: 10.1111/hepr.12681

Links

Wiley | PDF

Tools

Export citation

Search in Google Scholar

ITPA polymorphism effects on decrease of hemoglobin during simeprevir, pegylated interferon and ribavirin combination treatment for chronic hepatitis C: ITPA SNP and simeprevir therapy

Journal article published in 2016 by Kei Morio, Michio Imamura, Yoshiiku Kawakami, Reona Morio, Masahiro Hatooka, Hiromi Kan, Hatsue Fujino, Takayuki Fukuhara, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Ayako Urabe, Satoe Yokoyama, Yuko Nagaoki and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO